METHOD FOR PREVENTION OF VENOUS THROMBOEMBOLIA IN PATIENTS WITH CERVICAL CANCER

FIELD: medicine. SUBSTANCE: for prevention of venous thromboembolism in patients with cervical cancer, a patient receives low molecular weight heparins (LMWH) in prophylactic doses considering the risk factors. LMWH dose is prescribed from the first day of hospitalization considering the drug recalculation factor depending on the stage of disease and tumour histological subtype: at stage I of cervical cancer with unchanged coagulogram, a prophylactic LMWH dose with a coefficient equal to 1 is prescribed, and in the presence of high thrombosis in this group of patients, a prophylactic LMWH dose with a coefficient of 1.25 is prescribed; for patients with stage II squamous cell cervical cancer, a prophylactic LMWH dose with a coefficient of 1.25 is prescribed, and for stages III and IV, prophylactic LMWH dose with a coefficient of 1.5 is prescribed; for patients with stage II cervical adenocarcinoma and adenosquamous cervical carcinoma, a prophylactic LMWH dose with a coefficient of 1.5; for patients with stages III and IV cervical adenocarcinoma and adenosquamous cervical carcinoma, a prophylactic LMWH dose with a coefficient of 1.75 is prescribed. EFFECT: invention allows to prevent development of complications, extend and improve the quality of life of patients undergoing surgery for cervical cancer.